Shaozheng Wang, Zongchao Zuo, Zhangyi Ouyang, Xinyu Liu, Junke Wang, Yajun Shan, Ruoxi Meng, Zhenhu Zhao, Xiaolan Liu, Xiaoyan Liu, Yiguang Jin, Zhongtang Li, Hong Zhang, Limei Wang, Yuwen Cong
To date only four recombinant growth factors, including Filgrastim (rhG-CSF), have been approved by FDA as radiomitigators to ameliorate hematopoietic acute radiation syndrome (H-ARS). These approved agents are not stable under room-temperature, needing to be stored at 2-8 °C, and would not be feasible in a mass casualty scenario where rapid and cost-effective intervention is crucial. Delta-tocotrienol (δ-T3H), the most potent G-CSF-inducing agent among vitamin E isoforms, exhibited efficiency and selectivity on G-CSF production in comparison with TLR and STING agonists in mice...
February 15, 2024: Biochemical and Biophysical Research Communications